2021 Q3 Form 10-Q Financial Statement
#000121390022032831 Filed on June 14, 2022
Income Statement
| Concept | 2021 Q3 |
|---|---|
| Revenue | $969.0K |
| YoY Change | -21.85% |
| Cost Of Revenue | |
| YoY Change | |
| Gross Profit | |
| YoY Change | |
| Gross Profit Margin | |
| Selling, General & Admin | $12.05M |
| YoY Change | 333.49% |
| % of Gross Profit | |
| Research & Development | $1.562M |
| YoY Change | 47.36% |
| % of Gross Profit | |
| Depreciation & Amortization | $381.0K |
| YoY Change | -17.17% |
| % of Gross Profit | |
| Operating Expenses | $13.99M |
| YoY Change | 225.44% |
| Operating Profit | |
| YoY Change | |
| Interest Expense | $487.0K |
| YoY Change | -123.08% |
| % of Operating Profit | |
| Other Income/Expense, Net | |
| YoY Change | |
| Pretax Income | -$12.54M |
| YoY Change | 121.52% |
| Income Tax | $5.000K |
| % Of Pretax Income | |
| Net Earnings | -$12.38M |
| YoY Change | 128.84% |
| Net Earnings / Revenue | -1277.61% |
| Basic Earnings Per Share | |
| Diluted Earnings Per Share | -$709.9K |
| COMMON SHARES | |
| Basic Shares Outstanding | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q3 |
|---|---|
| SHORT-TERM ASSETS | |
| Cash & Short-Term Investments | $7.854M |
| YoY Change | 26.68% |
| Cash & Equivalents | $7.854M |
| Short-Term Investments | |
| Other Short-Term Assets | $5.964M |
| YoY Change | 80.73% |
| Inventory | |
| Prepaid Expenses | |
| Receivables | $346.0K |
| Other Receivables | $600.0K |
| Total Short-Term Assets | $14.76M |
| YoY Change | 50.65% |
| LONG-TERM ASSETS | |
| Property, Plant & Equipment | $43.24M |
| YoY Change | -2.62% |
| Goodwill | |
| YoY Change | |
| Intangibles | |
| YoY Change | |
| Long-Term Investments | $85.46M |
| YoY Change | 8.32% |
| Other Assets | $1.517M |
| YoY Change | -5.19% |
| Total Long-Term Assets | $139.3M |
| YoY Change | 10.11% |
| TOTAL ASSETS | |
| Total Short-Term Assets | $14.76M |
| Total Long-Term Assets | $139.3M |
| Total Assets | $154.1M |
| YoY Change | 13.03% |
| SHORT-TERM LIABILITIES | |
| YoY Change | |
| Accounts Payable | $1.296M |
| YoY Change | 44.0% |
| Accrued Expenses | $1.227M |
| YoY Change | 2.25% |
| Deferred Revenue | |
| YoY Change | |
| Short-Term Debt | $14.53M |
| YoY Change | |
| Long-Term Debt Due | |
| YoY Change | |
| Total Short-Term Liabilities | $17.30M |
| YoY Change | 203.56% |
| LONG-TERM LIABILITIES | |
| Long-Term Debt | $0.00 |
| YoY Change | |
| Other Long-Term Liabilities | $48.00K |
| YoY Change | -52.0% |
| Total Long-Term Liabilities | $48.00K |
| YoY Change | -52.0% |
| TOTAL LIABILITIES | |
| Total Short-Term Liabilities | $17.30M |
| Total Long-Term Liabilities | $48.00K |
| Total Liabilities | $31.77M |
| YoY Change | 62.92% |
| SHAREHOLDERS EQUITY | |
| Retained Earnings | -$40.80M |
| YoY Change | |
| Common Stock | $8.000K |
| YoY Change | |
| Preferred Stock | |
| YoY Change | |
| Treasury Stock (at cost) | |
| YoY Change | |
| Treasury Stock Shares | |
| Shareholders Equity | $122.3M |
| YoY Change | |
| Total Liabilities & Shareholders Equity | $154.1M |
| YoY Change | 13.03% |
Cashflow Statement
| Concept | 2021 Q3 |
|---|---|
| OPERATING ACTIVITIES | |
| Net Income | -$12.38M |
| YoY Change | 128.84% |
| Depreciation, Depletion And Amortization | $381.0K |
| YoY Change | -17.17% |
| Cash From Operating Activities | -$6.981M |
| YoY Change | 313.08% |
| INVESTING ACTIVITIES | |
| Capital Expenditures | $31.00K |
| YoY Change | -177.5% |
| Acquisitions | |
| YoY Change | |
| Other Investing Activities | $500.0K |
| YoY Change | -200.0% |
| Cash From Investing Activities | $531.0K |
| YoY Change | -198.33% |
| FINANCING ACTIVITIES | |
| Cash Dividend Paid | |
| YoY Change | |
| Common Stock Issuance & Retirement, Net | |
| YoY Change | |
| Debt Paid & Issued, Net | |
| YoY Change | |
| Cash From Financing Activities | 14.53M |
| YoY Change | |
| NET CHANGE | |
| Cash From Operating Activities | -6.981M |
| Cash From Investing Activities | 531.0K |
| Cash From Financing Activities | 14.53M |
| Net Change In Cash | 8.078M |
| YoY Change | -462.24% |
| FREE CASH FLOW | |
| Cash From Operating Activities | -$6.981M |
| Capital Expenditures | $31.00K |
| Free Cash Flow | -$7.012M |
| YoY Change | 324.97% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001713863 | ||
| CY2021Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
USD | |
| CY2022Q2 | rfl |
Revenues Other Related Party
RevenuesOtherRelatedParty
|
USD | |
| rfl |
Provision For Loss On Receivable Pursuant To Line Of Credit
ProvisionForLossOnReceivablePursuantToLineOfCredit
|
USD | ||
| CY2022Q2 | rfl |
Provision For Losses On Related Party Receivables
ProvisionForLossesOnRelatedPartyReceivables
|
USD | |
| CY2021Q2 | rfl |
Provision For Losses On Related Party Receivables
ProvisionForLossesOnRelatedPartyReceivables
|
USD | |
| rfl |
Provision For Losses On Related Party Receivables
ProvisionForLossesOnRelatedPartyReceivables
|
USD | ||
| CY2022Q2 | us-gaap |
Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
|
USD | |
| us-gaap |
Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
|
USD | ||
| CY2022Q2 | us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
USD | |
| CY2021Q2 | us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
USD | |
| us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
USD | ||
| CY2022Q2 | us-gaap |
Impairment Of Investments
ImpairmentOfInvestments
|
USD | |
| CY2021Q2 | us-gaap |
Impairment Of Investments
ImpairmentOfInvestments
|
USD | |
| us-gaap |
Impairment Of Investments
ImpairmentOfInvestments
|
USD | ||
| CY2022Q2 | rfl |
Impairment Of Cost Method Investment Rafael Pharmaceuticals
ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals
|
USD | |
| CY2021Q2 | rfl |
Impairment Of Cost Method Investment Rafael Pharmaceuticals
ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals
|
USD | |
| rfl |
Impairment Of Cost Method Investment Rafael Pharmaceuticals
ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals
|
USD | ||
| CY2022Q2 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
USD | |
| CY2022Q2 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
|
USD | |
| us-gaap |
Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
|
USD | ||
| us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
USD | ||
| us-gaap |
Impairment Of Investments
ImpairmentOfInvestments
|
USD | ||
| rfl |
Impairment Of Cost Method Investment Rafael Pharmaceuticals
ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals
|
USD | ||
| rfl |
Impairment Altira
ImpairmentAltira
|
USD | ||
| rfl |
Provision For Loss On Receivable Pursuant To Line Of Credit
ProvisionForLossOnReceivablePursuantToLineOfCredit
|
USD | ||
| rfl |
Provision For Losses On Related Party Receivables
ProvisionForLossesOnRelatedPartyReceivables
|
USD | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
USD | ||
| us-gaap |
Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
|
USD | ||
| rfl |
Payment To Rafael Pharmaceuticals Pursuant To Line Of Credit
PaymentToRafaelPharmaceuticalsPursuantToLineOfCredit
|
USD | ||
| us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
USD | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
USD | ||
| us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
USD | ||
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
USD | ||
| rfl |
Contribution From Noncontrolling Interest Of Consolidated Entity
ContributionFromNoncontrollingInterestOfConsolidatedEntity
|
USD | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
USD | ||
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
USD | ||
| us-gaap |
Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
|
USD | ||
| rfl |
Common Shares Issued For Payment Of Purchase Price For Altira Equity
CommonSharesIssuedForPaymentOfPurchasePriceForAltiraEquity
|
USD | ||
| rfl |
Acquisition Of Additional Ownership Interest In Lipo Medix
AcquisitionOfAdditionalOwnershipInterestInLipoMedix
|
USD | ||
| CY2022Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
|
USD | |
| CY2021Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
|
USD | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
|
USD | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
|||
| CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
USD | |
| CY2022Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
USD | |
| CY2022Q2 | rfl |
Forfeiture Of Rs Us Within General And Administrative
ForfeitureOfRSUsWithinGeneralAndAdministrative
|
USD | |
| CY2021Q2 | rfl |
Forfeiture Of Rs Us Within General And Administrative
ForfeitureOfRSUsWithinGeneralAndAdministrative
|
USD | |
| rfl |
Forfeiture Of Rs Us Within General And Administrative
ForfeitureOfRSUsWithinGeneralAndAdministrative
|
USD |
